Title : Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function.

Pub. Date : 2020 Oct

PMID : 32777959






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Materials & methods: We report successful clinical experience using ruxolitinib as adjuvant therapy to treat steroid-refractory CRS, which was related to CD22/CD19 chimeric antigen receptor-modified T cell sequential infusion, in a patient with Philadelphia chromosome-like acute lymphoblastic leukemia. Steroids CD19 molecule Homo sapiens